No Q2 call yet for a Colorado medtech; San Diego biotech collabs with MD Anderson
A Littleton, CO, sleep apnea medtech was supposed to hold its Q2 earnings call on Aug. 15, then Aug. 22 and now maybe not for weeks.
It could take “several weeks” before Vivos Therapeutics resolves issues with a “technical reevaluation of our revenue recognition policy,” the company said Monday after the closing bell. Vivos CEO Kirk Huntsman said the delay is “unrelated to the overall health” of the company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.